TY - ABST T1 - Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients Y1 - 2016 A1 - Liontos, M. A1 - Trigka, E.-A. A1 - P Korkolopoulou A1 - Tzannis, K. A1 - Lainakis, G. A1 - Koutsoukos, K. A1 - Kostouros, E. A1 - Lykka, M. A1 - Papandreou, C.N. A1 - Karavasilis, V. A1 - Christodoulou, C. A1 - Papatsoris, A. A1 - Skolarikos, A. A1 - Varkarakis, I. A1 - Adamakis, I. A1 - Alamanis, C. A1 - Stravodimos, K. A1 - Mitropoulos, D. A1 - Deliveliotis, C. A1 - Constantinidis, C.A. A1 - Saetta, A. A1 - Patsouris, E. A1 - Dimopoulos, M.Α. A1 - Bamias, A. KW - mRCC KW - mTOR KW - Sunitinib KW - VEGF AB - Purpose: To identify prognostic molecular profiles in patients with mRCC treated with sunitinib, we performed immunohistochemical analysis for VEGF and PI3K/Akt/mTOR pathway components. Methods: The immunohistochemical expression of VEGF, p85α, p110γ, PTEN, p-Akt, p-mTOR, p-4E-BP1 and p-p70S6K was studied in 79 patients with mRCC who received first-line treatment with sunitinib. Expression was correlated with clinicopathological features and survival. Results: VEGF was highly expressed (median H-Score 150), while positivity for the markers of the PI3K/Akt/mTOR pathway was: p85α 43/66 (65 %), p110γ41/60 (68 %), PTEN 32/64 (50 %), p-Akt57/63 (90 %), p-mTOR48/64 (75 %), p-4E-BP1 58/64 (90 %) and p-p70S6K 60/65 (92 %). No single immunohistochemical marker was found to have prognostic significance. Instead, the combination of increased p-mTOR and low VEGF expression was adversely correlated with overall survival (OS) (3.2 vs. 16.9 months, P = 0.001). Conclusion: Immunohistochemistry for VEGF and p-mTOR proteins may discriminate patients refractory to first-line sunitinib with poor prognosis. Prospective validation of our findings is needed. © 2016 Springer-Verlag Berlin Heidelberg JF - World Journal of Urology UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978107446&doi=10.1007%2fs00345-016-1890-7&partnerID=40&md5=68e45db77c26827cf8d30fd2ffea240a N1 - Export Date: 21 February 2017Article in Press ER -